Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia

Pharmacological Research

Volumn 54, Issue 3, 2006, Pages 203-207

  Molčányiová, Angela ^a   Stančáková, Alena ^b   Javorský, Martin ^b   Tkáč, Ivan ^b  

^a LABMED   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Antioxidant protection; Combined hyperlipidemia; Glutathione peroxidase; Hypercholesterolemia; LDL oxidation; Simvastatin

Indexed keywords

ALKADIENE; APOLIPOPROTEIN B; GLUTATHIONE PEROXIDASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; OXIDATION; PRIORITY JOURNAL;

EID: 33746324261     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.04.009     Document Type: Article

References (44)

1. The Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
2. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., Macfarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl J Med 333 (1995) 1301-1307
3. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl J Med 335 (1996) 1001-1009
4. Ohara Y., Peterson T.E., Sayegh H.S., Subramanian R.R., Wilcox J.N., and Harrison D.G. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 92 (1995) 898-903
5. Reilly M.P., Pratico' D., Delanty N., DiMinno G., Tremoli E., Rader D., et al. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98 (1998) 2822-2828
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 320 (1989) 915-924
7. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (1990) 160-162
8. Frostegard J., Haegerstrand A., Gidlund M., and Nilsson J. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90 (1991) 119-126
9. Frostegard J., Nilsson J., Haegerstrand A., Hamsten A., Wigzell H., and Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci USA 87 (1990) 904-908
10. Koba S., Pakala R., Watanabe T., Katagiri T., and Benedict C.R. Synergistic interaction between thromboxane A2 and mildly oxidized low density lipoproteins on vascular smooth muscle cell proliferation. Prostaglandins Leukot Essent Fatty Acids 63 (2000) 329-335
11. Regnstrom J., Nilsson J., Tornvall P., Landou C., and Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339 (1992) 1183-1186
12. Raitakari O.T., Toikka J.O., Laine H., Ahotupa M., Iida H., Viikari J.S., et al. Reduced myocardial flow reserve relates to increased carotid intima-media thickness in healthy young men. Atherosclerosis 156 (2001) 469-475
13. Toikka J.O., Laine H., Ahotupa M., Haapanen A., Viikari J.S., Hartiala J.J., et al. Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension 36 (2000) 929-933
14. Vasankari T., Ahotupa M., Toikka J., Mikkola J., Irjala K., Pasanen P., et al. LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis 155 (2001) 403-412
15. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89 (2002) 386-389
16. Rosenson R.S., Wolff D., and Tangney C.C. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond) 106 (2004) 215-217
17. Ahotupa M., Ruutu M., and Mantyla E. Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 29 (1996) 139-144
18. Ohkawa I., Shiga S., and Kageyama M. An esterase on the outer membrane of Pseudomonas aeruginosa for the hydrolysis of long chain acyl esters. J Biochem (Tokyo) 86 (1979) 643-656
19. Paglia D.E., and Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70 (1967) 158-169
20. Kappus H. Lipid peroxidation: mechanisms, analysis, enzymology and biological relevance. In: Sies H. (Ed). Oxidative stress (1985), Academic Press, London 273-310
21. Ahotupa M., Marniemi J., Lehtimäki T., Talvinen K., Raitakari O.T., Vasankari T., et al. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem 31 (1998) 257-261
22. Li D.Y., Chen H.J., and Mehta J.L. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 52 (2001) 130-135
23. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
24. Yasuhara M., Suzumura K., Tanaka K., Takahashi M., Aoki S., Odawara A., et al. Fluvastatin, an HMG-CoA reductase inhibitor, protects LDL from oxidative modification in hypercholesterolemic rabbits. Biol Pharm Bull 23 (2000) 570-574
25. Giroux L.M., Davignon J., and Naruszewicz M. Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1165 (1993) 335-338
26. Inami S., Okamatsu K., Takano M., Takagi G., Sakai S., Sano J., et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J 45 (2004) 969-975
27. Inoue T., Hayashi M., Takayanagi K., and Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients. Atherosclerosis 160 (2002) 369-376
28. van Tits L.J., Smilde T.J., van Wissen S., de Graaf J., Kastelein J.J., and Stalenhoef A.F. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 52 (2004) 177-184
29. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia. Am J Cardiol 89 (2002) 386-389
30. Vasankari T., Ahotupa M., Viikari J., Nuotio I., Vuorenmaa T., Strandberg T., et al. Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation. Atherosclerosis 179 (2005) 207-209
31. Bredie S.J., de Bruin T.W., Demacker P.N., Kastelein J.J., and Stalenhoef A.F. Comparison of gemfibrozil ' simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75 (1995) 348-353
32. Škrha J., Štulc T., Hilgertová J., Weiserová H., Kvasnička J., and Češka R. Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. Eur J Pharmacol 493 (2004) 183-189
33. Scheffer P.G., Teerlink T., and Heine R.J. Clinical significance of the physiochemical properties of LDL in type 2 diabetes. Diabetologia 48 (2005) 808-816
34. McKenney J.M., McCormick L.S., Schaefer E.J., Black D.M., and Watkins M.L. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88 (2001) 270-274
35. Forster L.F., Stewart G., Bedford D., Stewart J.P., Rogers E., Shepherd J., et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis 164 (2002) 129-145
36. Otvos J.D., Shalaurova I., Freedman D.S., and Rosenson R.S. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 160 (2002) 41-48
37. Caslake M.J., Stewart G., Day S.P., Daly E., McTaggart F., Chapman M.J., et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 171 (2003) 245-253
38. Glass C.K., and Witztum J.L. Atherosclerosis - the road ahead. Cell 104 (2001) 503-516
39. Guo Z., Van Remmen H., Yang H., Chen X., Mele J., Vijg J., et al. Changes in expression of antioxidant enzymes affect cell-mediated LDL oxidation and oxidized LDL-induced apoptosis in mouse aortic cells. Arterioscler Thromb Vasc Biol 21 (2001) 1131-1138
40. Lapenna D., de Gioia S., Ciofani G., Mezzetti A., Ucchino S., Calafiore A.M., et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation 97 (1998) 1930-1934
41. Luo J.D., Zhang W.W., Zhang G.P., Zhong B.H., and Ou H.J. Effects of simvastatin on activities of endogenous antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy. Acta Pharmacol Sin 23 (2002) 124-128
42. Carneado J., Alvarez de Sotomayor M., Perez-Guerrero C., Jimenez L., Herrera M.D., Pamies E., et al. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect. J Hypertens 20 (2002) 429-437
43. Passi S., Stancato A., Aleo E., Dmitrieva A., and Littarru G.P. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors 18 (2003) 113-124
44. Ghayour-Mobarhan M., Lamb D.J., Taylor A., Vaidya N., Livingstone C., Wang T., et al. Effect of statin therapy on serum trace element status in dyslipidaemic subjects. J Trace Elem Med Biol 19 (2005) 61-67